Inhaled virus takes on lung tumors in new trial

NCT ID NCT06228326

Recruiting now Disease control Sponsor: Krystal Biotech, Inc. Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests an inhaled treatment called KB707, a modified herpes virus designed to trigger the immune system against lung tumors. It is for adults with advanced solid tumors that have spread to the lungs and who have run out of standard options. The trial will test KB707 alone and in combination with Keytruda or chemotherapy to see if it is safe and can shrink tumors.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: genetically modified herpes simplex virus (KB707)
What this could lead to: If successful, this could offer a new inhaled treatment option for people with advanced lung cancers that have stopped responding to standard therapies.
What could go wrong: This is an early-phase trial (Phase 1/2) with a small number of participants, so safety and effectiveness are not yet proven. The virus-based therapy may cause side effects or fail to shrink tumors.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cancer lung cancer lung neoplasm metastatic malignant neoplasm neoplasm non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADVANCED CANCER LUNG CANCER (NON-SMALL CELL) LUNG CANCER (NSCLC) LUNG CANCER METASTATIC SOLID TUMOR, ADULT

Contacts and locations

Locations

BRCR Global
RECRUITING

Weston, Florida, 33326, United States
Cleveland Clinic
RECRUITING

Cleveland, Ohio, 44195, United States
Emad Ibrahim MD Inc
RECRUITING

Redlands, California, 92373, United States
Gabrail Cancer Center Research
RECRUITING

Canton, Ohio, 44718, United States
Henry Ford Health
RECRUITING

Detroit, Michigan, 48202, United States
HonorHealth Research Institute
RECRUITING

Scottsdale, Arizona, 85258, United States
IU Simon Comprehensive Cancer Center
TERMINATED

Indianapolis, Indiana, 46202, United States
Ochsner/MD Anderson Cancer Center
RECRUITING

New Orleans, Louisiana, 70121, United States
Precision NextGen Oncology
RECRUITING

Beverly Hills, California, 90212, United States
Renovatio Clinical
TERMINATED

El Paso, Texas, 79915, United States
Renovatio Clinical
TERMINATED

The Woodlands, Texas, 77380, United States
Sarah Cannon Research Institute
RECRUITING

Nasville, Tennessee, 37203, United States
UPMC Hillman Cancer Center
TERMINATED

Pittsburgh, Pennsylvania, 15232, United States
XCancer Research Network/Dothan Hematology & Oncology
RECRUITING

Dothan, Alabama, 36303, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.